Scientists at the Institut Pasteur have developed an innovative strategy to combat SARS-CoV-2. Rather than targeting a virus in constant mutation, they propose blocking the gateway used by the virus to penetrate our cells. This is achieved by nasal administration of an antibody that protects against all known variants, paving the way for new therapies aimed at vulnerable individuals. This work, which has emerged from an unprecedented collaboration involving five research units and five technology core facilities at the Institut Pasteur and the Department of Applications of Research and Relations with Industrials (DARRI), is published in Nature Communications.

Find out more